| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |